Global Infectious Disease Testing Using PCR for IVD Market Size By Type (Direct Detection, Indirect Detection), By Application (Hospitals, Laboratory), By Region, And Segment Forecasts, 2023 to 2032

The Global Infectious Disease Testing Using PCR for IVD Market was valued at USD 7.4 billion in 2023 and is projected to reach USD 13.1 billion by 2031, growing at a CAGR of 7.3% during the forecast period from 2023 to 2031. The market growth is driven by increasing global incidences of infectious diseases, advancements in PCR (polymerase chain reaction) technology, and the rising demand for rapid, sensitive, and accurate diagnostic tools within clinical laboratories and point-of-care settings. The integration of real-time PCR with IVD platforms has significantly improved the efficiency of diagnosing infections such as respiratory viruses, STIs, and emerging zoonotic pathogens.

Drivers:

1. Rising Global Burden of Infectious Diseases:

The increasing prevalence of infectious diseases such as tuberculosis, HIV, hepatitis, and COVID-19 is prompting the demand for reliable diagnostic testing. PCR-based IVD offers high sensitivity and specificity, making it a preferred method for early detection and disease monitoring.

2. Technological Advancements in PCR Platforms:

Innovations like multiplex PCR, digital PCR, and automated sample preparation are enhancing the capabilities of diagnostic systems, allowing faster turnaround times and higher throughput, which are essential in outbreak scenarios and high-volume testing environments.

3. Growing Demand for Point-of-Care Testing:

There is a significant shift toward decentralized diagnostics. Portable PCR-based IVD devices are gaining traction in clinics, rural health centers, and emergency care settings, providing timely diagnosis and enabling rapid treatment decisions.

Restraints:

1. High Cost of Equipment and Testing Kits:

PCR instruments and reagents are relatively expensive, limiting their adoption in resource-limited settings. The need for skilled professionals and infrastructure further adds to the operational cost.

2. Risk of Contamination and False Results:

Despite high sensitivity, PCR tests are susceptible to cross-contamination and false positives/negatives, which can impact clinical decisions and hinder trust among healthcare providers.

Opportunity:

1. Expansion in Emerging Markets:

Increasing healthcare investments and government initiatives for infectious disease control in Asia-Pacific, Latin America, and Africa present immense growth opportunities. Diagnostic companies are targeting these regions with cost-effective, portable PCR solutions.

2. Integration with AI and Cloud-based Data Systems:

Combining PCR testing with AI-driven data analytics and cloud reporting enables real-time surveillance, outbreak tracking, and epidemiological insights, offering new revenue streams for IVD solution providers.

Market by System Type Insights:

The Real-Time PCR (qPCR) segment held the dominant share in 2023 due to its ability to provide quantitative insights with high accuracy. It is widely used in clinical laboratories for detecting a wide range of pathogens. Digital PCR is anticipated to grow at the fastest rate during the forecast period, owing to its superior precision and growing application in low-abundance target detection, including in asymptomatic carriers.

Market by End-use Insights:

Hospitals and Diagnostic Laboratories were the leading end-users in 2023, collectively accounting for more than 60% of the market. The increasing need for confirmatory testing and disease monitoring in hospital settings is driving adoption. Meanwhile, the Point-of-Care Testing segment is expected to experience robust growth due to its utility in remote locations, field settings, and during pandemics.

Market by Regional Insights:

North America dominated the global market in 2023, driven by its advanced healthcare infrastructure, widespread adoption of molecular diagnostics, and substantial R&D investments. Asia-Pacific is projected to exhibit the highest CAGR, attributed to growing awareness, increasing healthcare expenditure, and proactive governmental disease surveillance programs.

Competitive Scenario:

Key players in the market include Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, Bio-Rad Laboratories, QIAGEN N.V., Cepheid (Danaher Corporation), and Becton, Dickinson and Company. These firms are focused on launching new PCR platforms, expanding test menus, and forming partnerships to expand their global footprint.

Scope of Work – Global Infectious Disease Testing Using PCR for IVD Market

Report Metric Details

Market Size (2023) USD 7.4 billion

Projected Market Size (2031) USD 13.1 billion

CAGR (2023–2031) 7.3%

Market Segments By System Type (Real-Time PCR, Digital PCR), By End-use (Hospitals, Diagnostics Labs, Point-of-Care Settings), By Region

Growth Drivers Rise in infectious diseases, PCR technology advancements, growing POC demand

Opportunities Emerging market expansion, AI and cloud integration

Key Market Developments:

2023: Roche Diagnostics launched a new multiplex PCR panel capable of detecting 20 pathogens in a single assay, targeting respiratory and gastrointestinal infections.

2024: QIAGEN expanded its QIAstat-Dx platform into emerging markets with CE-marked kits for dengue and chikungunya detection.

2025: Thermo Fisher Scientific acquired a digital PCR start-up to strengthen its capabilities in low copy number virus detection, notably for HIV and HPV.

FAQs:

1. What is the current market size of the Global Infectious Disease Testing Using PCR for IVD Market?

The market was valued at USD 7.4 billion in 2023.

2. What is the major growth driver of the Global Infectious Disease Testing Using PCR for IVD Market?

The primary growth driver is the rising global burden of infectious diseases and the adoption of advanced PCR-based diagnostics.

3. Which is the largest region during the forecast period in the Global Infectious Disease Testing Using PCR for IVD Market?

North America is projected to retain the largest market share through 2031.

4. Which segment accounted for the largest market share in Global Infectious Disease Testing Using PCR for IVD Market?

The Real-Time PCR segment held the largest share in 2023 due to its widespread clinical utility.

5. Who are the key market players in the Global Infectious Disease Testing Using PCR for IVD Market?

Major players include Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, Bio-Rad Laboratories, QIAGEN, and Cepheid.